Recently, CXCR4-positive CTCs were shown to persist in the blood of prostate cancer patients treated with radiotherapy for up to 3 months, suggesting that CXCR4-positive CTCs may represent aggressive CTC subclones that contribute to treatment resistance [23]. Here, CXCR4 is linked to prostate carcinoma.